CD274 and ovarian carcinoma: In this regard, in newly diagnosed stage III or IV ovarian carcinoma, the IMagyn050/GOG 3015/ENGOT-OV39 phase III trial (NCT03038100) evaluated the addition of the PD-L1 inhibitor atezolizumab to standard platinum-based chemotherapy and bevacizumab.